ARDT:NYE-Ardent Health Partners, Inc. (USD)

COMMON STOCK | Medical Care Facilities |

Last Closing

USD 16.07

Change

0.00 (0.00)%

Market Cap

USD 2.59B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
HCA HCA Holdings Inc

-1.86 (-0.61%)

USD 76.91B
DVA DaVita HealthCare Partners Inc

+0.48 (+0.31%)

USD 13.14B
THC Tenet Healthcare Corporation

-1.76 (-1.36%)

USD 12.31B
UHS Universal Health Services Inc

-0.09 (-0.05%)

USD 11.60B
EHC Encompass Health Corp

+0.17 (+0.18%)

USD 9.52B
CHE Chemed Corp

+2.75 (+0.53%)

USD 7.84B
CON Concentra Group Holdings Paren..

+0.12 (+0.59%)

USD 2.93B
NHC National HealthCare Corporatio..

+0.47 (+0.42%)

USD 1.90B
BKD Brookdale Senior Living Inc

+0.06 (+1.18%)

USD 1.11B
AMN AMN Healthcare Services Inc

+0.71 (+3.04%)

USD 1.00B

ETFs Containing ARDT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.59B 67% D+ 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.